Drugs of Abuse (DOA) Testing Global Market Report 2024

The drugs of abuse (doa) testing market size has grown strongly in recent years. It will grow from $6.6 billion in 2023 to $7.25 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth witnessed in the historical period can be ascribed to factors such as government regulations and workplace policies, pre-employment screening practices, law enforcement and legal procedures, drug rehabilitation programs, and compliance measures within the transportation industry.

The drugs of abuse (doa) testing market size is expected to see strong growth in the next few years. It will grow to $10.48 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The projected growth in the upcoming forecast period can be linked to the expansion of sports and athletics testing, heightened awareness and education regarding drug testing, a surge in drug-related crimes, the adoption of corporate wellness programs, and advancements in testing methods. Key trends anticipated in this period encompass the utilization of portable and handheld testing devices, the implementation of Laboratory Information Management Systems (LIMS), a focus on synthetic drug testing, a growing demand for cannabis testing, and the integration of artificial intelligence (AI) for result interpretation.

The rising demand for drug abuse treatment is anticipated to drive the growth of the drugs of abuse (DOA) testing market. Drug abuse, or substance abuse, involves the harmful use of substances by individuals. Drug testing plays a crucial role in identifying compounds not typically present in the body. The testing process includes screening tests followed by confirmatory tests to detect and verify the presence of specific substances. The growing need for drug abuse treatment is expected to contribute to the market's expansion. For example, in June 2021, the United Nations Office on Drugs and Crime (UNODC) reported in the World Drug Report that over 36 million individuals worldwide have drug use disorders. This increasing demand for drug abuse treatment is a key driver for the growth of the drugs of abuse (DOA) testing market.

The growing demand for hospitals is anticipated to drive the expansion of the drugs of abuse (DOA) testing market. Hospitals, as comprehensive healthcare institutions, play a crucial role in delivering a broad spectrum of medical services, treatment, and care for individuals facing illness or injury. The integration of drugs of abuse (DOA) testing within hospitals facilitates early detection of substance abuse, enabling customized treatment plans, enhancing clinical decision-making, ensuring patient safety, and contributing to public health, workplace safety, and efficient healthcare resource utilization. As of August 2023, there are reported to be 1148 hospitals in the UK, emphasizing the significant role hospitals play in healthcare services. Hence, the increasing demand for hospitals is a key factor propelling the growth of the drugs of abuse (DOA) testing market.

Major players in the drugs of abuse (DOA) testing market are directing their efforts towards developing cutting-edge products, including software-as-a-service (SaaS) platforms, to reinforce their market presence. Software-as-a-Service (SaaS) represents a software distribution model where applications are hosted by a third-party provider and accessed by customers over the internet. A notable example is the introduction of the Addison drug discovery software by Merck KGaA, a US-based science and technology company, in December 2023. This software accelerates drug development and enhances the success rate of novel medications and therapies by integrating computer-aided drug design, machine learning, and generative AI. Addison provides recommendations on optimal methods for synthesizing medications, bridging the gap between virtual molecule design and practical manufacturability. By extracting hidden insights from extensive datasets, the platform increases the likelihood of patients benefiting from innovative treatments.

Key players in the drugs of abuse (DOA) testing market are actively introducing new products, including advanced drug testing, to stay ahead in the market competition. Drug testing involves analyzing biological specimens, such as urine, to identify specific drugs or their metabolites. In December 2022, Omega Laboratories Inc., a US-based company specializing in forensic toxicology and hair testing services, launched urine drugs of abuse testing services. These services are known for their ease of use, rapid effects, and affordability. The laboratory provides accredited urine drug testing services, ensuring high quality and precision in test results. Serving over 6,000 clients worldwide, the organization employs both screening and confirmatory testing in urine drug abuse testing services to ensure the accuracy and reliability of the results.

In February 2021, Thermo Fisher Scientific Inc., a US-based company specializing in scientific research services, entered into a partnership with Mindray Medical International Limited, a China-based medical technology company. The collaboration aims to provide clinical laboratories, hospitals, and the criminal justice system with reliable and cost-effective tools for drug misuse screening. This partnership allows Thermo Fisher Scientific to address the needs of testing facilities looking to enhance or expand their testing capabilities, as well as those seeking to integrate and centralize their testing processes.

Major companies operating in the drugs of abuse (doa) testing market report are Siemens AG, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Zimmer Biomet Holdings Inc., bioMérieux Inc., Dragerwerk AG & Co. KGaA, Natera Inc., Aegis Sciences Corporation, NMS Labs, Clinical Reference Laboratory Inc., Cordant Health Solutions, Millennium Health, ACM Global Laboratories, Psychemedics Corporation, Alfa Scientific Designs Inc., Alere Toxicology Services, Omega Laboratories Inc., BioTek Laboratories, Premier Biotech Inc., Dominion Diagnostics LLC, Randox Toxicology Ltd., Cansford Laboratories Ltd., United States Drug Testing Laboratories Inc., Homology Medicines Inc., American Bio Medica Corporation, Confirm BioSciences, Immunalysis Corporation, Medtox Diagnostics Inc., Forensic Fluids Laboratories.

North America was the largest region in the drugs of abuse (DOA) testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global drugs of abuse (DOA) testing market report during the forecast period. The regions covered in the drugs of abuse (doa) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drugs of abuse (doa) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Drug of Abuse (DOA) testing encompasses various products and services, including analyzers, rapid testing devices, consumables, and laboratory services. Analyzers, automatic devices measuring chemical concentrations, play a crucial role in this domain. The testing involves sample types such as urine, hair, oral fluid, and breath, with applications in pain management, criminal justice, and workplace screening. End-users of DOA testing include hospitals, diagnostic laboratories, forensic laboratories, and other relevant entities.

The drugs of abuse (DOA) testing market research report is one of a series of new reports that provides drugs of abuse (DOA) testing market statistics, including drugs of abuse (DOA) testing industry global market size, regional shares, competitors with a drugs of abuse (DOA) testing market share, detailed drugs of abuse (DOA) testing market segments, market trends and opportunities, and any further data you may need to thrive in the drugs of abuse (DOA) testing industry. This drug of abuse (DOA) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs of abuse (DOA) testing market includes revenues earned by entities by providing services such as analyzers, rapid testing devices, consumables, and laboratory services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.